Recent trends in mortality due to testicular cancer in Ireland: a comparison with England and Wales

JOHN A THORNHILL, RONAN M CONROY, DANIEL G KELLY, ANTHONY WALSH, JAMES J FENNELLY AND JOHN M FITZPATRICK
From The Irish Testicular Tumour Registry, 5 Northumberland Road, Dublin 4, Ireland

SUMMARY In the period 1961–84, the number of deaths in Ireland due to testis cancer rose by 64%. This was due both to significant male population expansion (25-33%) and to an increased mortality rate. In the 25–34 years age group, one of the groups at highest risk, the mortality rate rose by 123%. In contrast, in England and Wales, although the male population has risen by 8.5% since 1961, the number of deaths has decreased by 17%. This is due to falling mortality rates, for example an 18% decrease in those aged 25–34 years. The highest rate of all occurred in those Irish over 75 years old. The changing Irish trends appear to lag behind those in England and Wales by some decades, and this raises important aetiological considerations.

Testis tumours are rare, accounting for approximately 1% of all male neoplasms.1 However, the incidence is reported to be increasing in several countries.2 This trend is particularly marked in Denmark3 whose annual rate of 8–9 per 105 males is much greater than in other countries where the annual incidence is generally low and between 2 and 3 per 105 male population.4

The importance of a rising incidence is underlined by two factors particularly relevant to this type of cancer. Firstly, traditional figures show that this disease affects men at crucial ages, that is, predominantly in the 20–40 years age group.5 It is now the fourth commonest cause of death in males aged 15–34 years6 and the leading cause of lethal cancer between 25 and 34 years,7 a time of life when not only is work productivity often high but likewise the number of dependents and financial and social commitments. Secondly, while one male in 500 will get the disease before the age of 50 and approximately 25% of those affected will die as a result, there is little doubt that multidisciplinary management in a specialist setting can now hope for a nearly 100% cure rate in early stage disease and almost 75% cure rate overall. Similar results are not achieved in any other solid tumour in males.7 This is because of major clinical advances, especially in the fields of chemotherapy,8 serum tumour markers9 and coordinated treatment.10

There has previously been no study of Irish incidence or mortality rates although reference has been made to possible rising figures.12 This investigation was therefore undertaken to obtain a comparative estimate of the magnitude of the problem of testicular cancer in Ireland, England and Wales and to gain a better insight into current trends in all regions.

Methods

Mortality data for Ireland were supplied by the Department of Health and the Central Statistics Office, and for England and Wales by the Office of Population Censuses and Surveys. The distribution of the male population at risk was calculated from supplied figures.

Both mortality and demographic data were analysed in three octennia: 1961–68, 1969–76, and 1977–84. Because of the rarity of this disease, deaths were pooled in ten-year age groups instead of the usual five. Likewise, to ensure meaningful reporting, children up to age 15 years and those older than 75 years were considered single groups.

To verify any trends in mortality rates, deaths were analysed by birth cohort. Cohorts born at extremes (eg, 1900 and 1959) are not directly comparable because of their wide age difference during the 24 year study period. In those born in interim years, however, there is good crossover, and within these limitations all data can be considered an accurate reflection of actual mortality rates.

To verify findings, it was considered necessary to test the reliability of the basic mortality data. All relevant Irish death certificates in the years 1980–84...
Recent trends in mortality due to testicular cancer in Ireland: a comparison with England and Wales

were individually scrutinised, and registry material for the same period was compared.

Results

The number of deaths due to testicular cancer in Ireland increased from 73 in 1961–68 to 120 in 1977–85, an increase of 64%. There was an increase of 25.3% in the male population over the 24 years. In contrast, the corresponding deaths in England and Wales decreased from 1736 to 1486, a reduction of 16.8% while the male population increased by 8.5%.

The age distribution of deaths and mortality rates in the period 1961–84 showed a peak at ages 25–34 years for all regions (fig. 1). In England and Wales the distribution was bimodal with moderate levels also seen in the elderly. The equivalent Irish rates showed a lesser peak in young adults, and the highest age specific rates of all occurred in Ireland in those over 75 years old.

Fig. 1 Comparative age specific mortality rates from testis cancer in Ireland and England/Wales 1961–84.

Fig. 2 Comparative age specific mortality rates in Ireland and England/Wales, 1961–68.

Fig. 3 Comparative age specific mortality rates in Ireland and England/Wales, 1969–76.

Fig. 4 Comparative age specific mortality rates in Ireland and England/Wales 1977–84.
Comparative trends in age specific mortality rates over the 24 years are illustrated (figs 2 to 4). There has been a marked increase in Irish rates over the period: 0·5 to 1·3 per 10^5 in ages 15–24 years, an increase of 156%; 0·75 to 1·77 in ages 25–34 years, an increase of 123%; and 2·11 to 2·39 in those older than 75 years, an increase of 13%. In contrast, rates in England and Wales have decreased in all age groups except the very elderly; 0·97 to 0·94 per 10^5 in ages 15–24 years, a decrease of 3%; 2·08 to 1·70 in ages 25–34 years, a decrease of 18%; and 1·40 to 1·50 in those over 75 years, an increase of 7%.

The end result of these opposing trends in mortality has been that the rates for ages 15–34 years in all regions are now very similar. This is in sharp contrast to the situation two decades ago. The relative very high rate in Ireland in those over 75 years has been consistently at variance with equivalent rates in the other countries. Age distribution has remained bimodal in England and Wales with diminishing accentuation whereas the trimodal character of Irish figures has developed and become more pronounced.

The mortality rates of ten year birth cohorts in Ireland are shown in figure 5. These confirm the rising trend in those aged 20–45 years, and show a consistent low incidence in those of middle age, while the evidence of a rising rate in old age is not outruled. Cohort rates for England and Wales (not illustrated) did not show significant alteration during the study period in accord with trends in actuarial mortality rates.

Inspection of the relevant Irish death certificates between 1980 and 1984 and comparison with equivalent registry material revealed some discrepancy in mortality data. One case (1·3% of total in period) of prostatic cancer was incorrectly coded as a testis cancer on the death certificate. Two cases (2·7% of total) were not germ-cell tumours; one leiomyosarcoma of old age and one rhabdomyosarcoma in a young adult. The registry also revealed one mortality in which testes cancer had not been entered on the death certificate when this may have been appropriate.

**Discussion**

The significance of the increasing Irish mortality rate, especially in the 15–44 years age group, is emphasised by study of the relevant subpopulation at risk. Its continued remarkable expansion, by 51% over 24 years, can be expected to yield an ever increasing number of cases in future decades. In England and Wales, a similar but much less marked demographic trend had a less significant effect on the number of deaths that occurred. Their combination of moderate population growth (8·4% in age group 15–44 years over 24 years) with falling mortality rates should ensure a continued decrease in the number of deaths from this disease.

The causes of increasing Irish rates in the 15–44 age group remain unexplained. The study of mortality data normally excludes details of histological classification but this study confirmed that nearly all tumours were of germ cell origin. Some studies have shown the incidence of teratomas to be rising more rapidly than seminomas and this phenomenon could explain the trend towards greater increases in younger age groups, confirmed by cohort studies. This theory is supported by the emergence of a lesser peak in mortality rates in ages 45–54 years, which could be specifically due to seminomas. Although the aetiology of testicular cancer remains obscure, the accepted predisposing factors of maleness, unilateral atrophy with infertility and ambiguous sex are unlikely to have altered over the study period. It is therefore likely that other causative factors were active. Better awareness and improved methods of diagnosis may, by increasing detection of testicular cancer, play a role in increasing apparent numbers; but, in contrast, recent advances in management should have reduced mortality rates. Major improvements in treatment results have been documented in England and Wales, and this could partially explain the falling rate. An evaluation of Irish treatment results is awaited but it is unlikely that the above factors, even if

---

*Results are accurate to the limits of the extrapolations shown.*

---

**Fig 5 Age specific mortality rates for male ten-year cohorts in Ireland.**
Recent trends in mortality due to testicular cancer in Ireland: a comparison with England and Wales

The authors wish to thank Miss V Freeman for typing the manuscript.

The Irish Testicular Tumour Registry is funded by grant from The Irish Cancer Society.

Address for reprints: Mr John A. Thornhill, The Irish Testicular Tumour Registry, 5 Northumberland Road, Dublin 4.

References

Recent trends in mortality due to testicular cancer in Ireland: a comparison with England and Wales.

J A Thornhill, R M Conroy, D G Kelly, A Walsh, J J Fennelly and J M Fitzpatrick

*J Epidemiol Community Health* 1986 40: 218-222
doi: 10.1136/jech.40.3.218

Updated information and services can be found at:
http://jech.bmj.com/content/40/3/218

*These include:*

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/